Scholarlink

Introduction <p>To clarify the uncertain association between maternal total triiodothyronine (TT3) levels and preeclampsia risk.</p> Methods <p>In a hospital-based cohort of pregnant women with universal thyroid testing, we assessed the association between TT3 and preeclampsia using directed acyclic graphs (DAG) to control confounders.</p> Results <p>Maternal TT3 levels were associated with preeclampsia risk, with an adjusted odd ratio (OR) of 2.32 (95% confidence interval (CI) 2.02–2.68) in women with the highest TT3 quartile comparing to those in the lowest quartile. A J-shaped association was identified for early onset preeclampsia, with particularly strong association when thyroid-stimulating hormone exceeded 2.5 μIU/mL (OR, 17.22, 95% CI 4.52–65.60). Gestational age &gt; 18&#xa0;weeks at measurement significantly modified the effect of TT3 on preeclampsia risk, with an interaction OR of 3.22 (95% CI 1.56–6.62).</p> Conclusion <p>Increased maternal TT3 levels were associated with preeclampsia. TT3 may contribute to preeclampsia pathogenesis and serve as a clinical biomarker, especially for early onset cases with thyroid dysfunction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between maternal circulating total triiodothyronine and subsequent risk of preeclampsia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月4日

查看全文
  • Jiang-Nan Wu,
  • Faustino R. Pérez-López,
  • Ignacio Rodríguez,
  • Li Yao,
  • Lu-Yi Mao

摘要

Introduction

To clarify the uncertain association between maternal total triiodothyronine (TT3) levels and preeclampsia risk.

Methods

In a hospital-based cohort of pregnant women with universal thyroid testing, we assessed the association between TT3 and preeclampsia using directed acyclic graphs (DAG) to control confounders.

Results

Maternal TT3 levels were associated with preeclampsia risk, with an adjusted odd ratio (OR) of 2.32 (95% confidence interval (CI) 2.02–2.68) in women with the highest TT3 quartile comparing to those in the lowest quartile. A J-shaped association was identified for early onset preeclampsia, with particularly strong association when thyroid-stimulating hormone exceeded 2.5 μIU/mL (OR, 17.22, 95% CI 4.52–65.60). Gestational age > 18 weeks at measurement significantly modified the effect of TT3 on preeclampsia risk, with an interaction OR of 3.22 (95% CI 1.56–6.62).

Conclusion

Increased maternal TT3 levels were associated with preeclampsia. TT3 may contribute to preeclampsia pathogenesis and serve as a clinical biomarker, especially for early onset cases with thyroid dysfunction.